Drug Use Surveillance for ADCETRIS Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Takeda
- 06 Nov 2018 New trial record
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.